Loading…
← CockpitCompetitor Analysis › 4507.T Shionogi & CoOpen in the cockpit ↗

Shionogi & Co4507.TCompetitor analysis, valuation and peers

Japan · JPY·Health Care›Pharmaceuticals: Major

Japanese pharma focused on infectious disease drugs (antivirals, antibiotics) and pain/CNS treatments.

Momentum leader 81
Mkt cap
$17.6B
US dollars, full cap
Free float
79%
of shares outstanding
$/day
$58.5M
20-day average traded
Fwd P/E
11.8×
forward earnings
ROIC−WACC
+1.2 pp
WACC 5.0%
Hurdle
-11 pp
Req g minus delivered
Next earnings
79 days
5 Feb 2027
Close · JPY¥3,175
1D-0.4%
1W+3.9%
1M+8.0%
3M+12.1%
6M+3.1%
YTD+13.0%
1Y+24.4%
ATR %2.8%
52w lowhigh15.5% off high

What Shionogi & does

Japanese pharma focused on infectious disease drugs (antivirals, antibiotics) and pain/CNS treatments.

Earns a large part of its income as royalties and dividends from ViiV Healthcare, the HIV drug company in which it holds a minority stake alongside GSK and Pfizer, so a key profit stream does not depend on its own sales force. Its own antivirals and antibiotics are sold to hospitals and, for the COVID drug, partly through government purchases.

Products and services

  • Xocova (COVID-19 antiviral)
  • Antibiotics (cefiderocol/Fetroja)
  • HIV drugs (via ViiV JV)
  • Pain/CNS drugs

Customers

  • Hospitals, infectious disease specialists, governm

Where it sits in the supply chain

  • Healthcare
  • Pharmaceuticals
  • Anti-infective & CNS drug development

What could go right

  • ViiV Healthcare HIV royalties
  • New antiviral/antibiotic launches

What could go wrong

  • COVID antiviral demand normalization
  • Patent cliffs on legacy drugs

Moat: narrow (IP / patents, process know-how). Deep expertise in antivirals/antibiotics plus an HIV royalty stream via a ViiV Healthcare stake.

Headquarters: Osaka, Japan · Founded: 1878 · Employees: 6,223

Named competitors

Shionogi & at a glance

Size Shionogi & (4507.T) is a Japan Health Care company (Pharmaceuticals: Major) with a market value of $17.6B, the 89th largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥3,175 on 18 Nov 2026.

Performance Over six months the shares gained 3.1%, against +5.4% for the median peer and -1.4% for the Japan market (cap-weighted) — 7th lowest of 21 in its peer set.

Growth Revenue grew 45.7% over the last twelve months (peer median +24.4%); the operating margin is 28.7% (peer median 18.9%).

Valuation It trades at 11.8× forward earnings against a peer median of 25.8× (4th cheapest of 20).

Price implies For today's price to make sense, revenue must grow about 0% a year for seven years (Req g). Recent delivered growth is +11%, so the hurdle is -11 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 1.2 points above its cost of capital (5.0% WACC).

Next results Next results expected around 5 Feb 2027 (exchange calendar; dates can move).

Relative performance

9010011021 May 202621 Aug 202618 Nov 2026Peer median 1074507.T 104
Six months, rebased to 100: Shionogi & against the median of its 20 peers (local-currency closes).

Shionogi & financials

Reported figures in JPY; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue¥637B¥500B¥438B¥435B¥427B
Revenue growth—+14%+1%+2%—
Gross profit¥485B¥405B¥365B¥369B¥357B
EBITDA¥242B¥188B¥181B¥190B¥178B
Net income¥241B¥205B¥170B¥162B¥185B
Free cash flow¥247B¥199B¥178B¥142B¥166B
Capital expenditure¥38.0B¥31.3B¥52.1B¥28.3B¥37.2B
Total debt¥683B¥684B¥21.9B¥11.6B¥9.41B

Quarterly statements and history in the cockpit →

Shionogi & competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+20%+40%+60%-10%0%+10%ASNDEXELTORNTPHARM1801SOBIJAZZORNAVALNY6446000538688506IPNSIGLAURUSLABSVTRS6990INCYZYDUSLIFEDRREDDY36924507.T6-month return →1-month return →
Up and to the right = strong over both horizons. Shionogi & is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%+150%+200%0×500×1,000×ASNDEXELTORNTPHARM1801SOBIALNY6446SIG69904507.TRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Shionogi & is the large dot.

Capital: growth delivered against growth the price implies

0%+50%+100%+150%0%50%100%150%ASNDEXELTORNTPHARM1801SOBIALNY6446SIGLAURUSLABSVTRS6990DRREDDY4507.TGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Shionogi & is the large dot.

Shionogi & competitors and peer comparison

Head to head with its named competitors (4507.T vs 4502.T vs 4568.T vs PFE)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Shionogi & 4507.T$17.6B+3%+46%29%11.8×0.2%
Takeda Pharmaceutical 4502.T$69.8B+30%+6%18%51.0×3.7%
Daiichi Sankyo 4568.T$31.4B+8%+17%13%18.4×7.6%
Pfizer PFE$160B+9%+1%26%9.9×-4.3%
GSK GSK.L$97.9B-3%+4%25%10.4×-0.1%
Merck & MRK$340B+23%+5%18%16.4×8.3%

How Shionogi & compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Shionogi & against its 20 peers (data as of 18 Nov 2026)
Measure4507.TPeer medianRank in peer set
1-month return+8.0%+5.7%7th highest of 21
6-month return+3.1%+5.4%7th lowest of 21
Distance from 52-week high-15.5%-7.2%7th lowest of 21
Revenue growth (TTM)+45.7%+24.4%5th highest of 21
Operating margin28.7%18.9%7th highest of 21
Forward P/E11.8×25.8×4th cheapest of 20
Growth the price implies (Req g, 7 yrs)0.2%11.4%7th least demanding of 19
Growth delivered (Del g)+11.0%+12.8%6th lowest of 19
Hurdle (Req g minus delivered)-10.8 pp-9.4 pp10th least demanding of 19
ROIC minus cost of capital+1.2 pp+8.0 pp8th lowest of 21
EV / EBITDA12.9×22.4×4th cheapest of 18
Net debt / EBITDA1.3×-0.1×5th most indebted of 18

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Shionogi & 4507.TJapan$17.6B+3%+46%29%11.8×0.2%+11.0%
Ascendis Pharma A/S ASNDUnited States$16.9B+12%+94%18%28.0×19.2%+152.4%
Exelixis EXELUnited States$16.7B+37%+9%40%17.7×-3.8%+18.6%
Torrent Pharmaceuticals TORNTPHARM.NSIndia$18.8B+3%+42%22%70.2×37.6%+11.3%
Innovent Biologics 1801.HKHong Kong$18.9B+4%+43%17%52.3×11.6%+26.8%
Swedish Orphan Biovitrum SOBI.STSweden$16.1B+6%+15%30%24.1×-2.1%+13.1%
Jazz Pharmaceuticals Public JAZZUnited States$15.9B+4%+13%25%9.3×-2.8%+12.5%
Orion ORNAV.HEFinland$15.7B+41%+34%38%23.6×-6.2%+11.7%
Alnylam Pharmaceuticals ALNYUnited States$20.0B-50%+56%20%21.2×0.5%+49.8%
PharmaEssentia 6446.TWTaiwan$15.0B+67%+78%40%31.9×23.7%+94.8%
Yunnan Baiyao 000538.SZChina$15.0B+11%+5%11%18.3×-0.2%+4.7%
Sichuan Biokin Pharmaceutical 688506.SSChina$14.9B-7%+14%-43%n/an/an/a
Ipsen IPN.PAFrance$14.8B+1%+14%30%10.8×-6.7%+7.2%
Sigma Healthcare SIG.AXAustralia$22.4B+2%+209%9%38.4×28.9%+26.1%
Laurus Labs LAURUSLABS.NSIndia$13.4B+73%+23%24%76.4×51.2%+7.3%
Viatris VTRSUnited States$23.3B+23%+5%11%7.5×11.2%+3.7%
Sichuan Kelun-Biotech Biopharmaceutical 6990.HKHong Kong$13.0B-1%+44%-38%1,176.1×55.3%+33.6%
Incyte INCYUnited States$24.0B+21%+25%12%15.1×14.2%+14.0%
Zydus Lifesciences ZYDUSLIFE.NSIndia$12.8B+18%+24%17%30.0×n/an/a
Dr. Reddy's Laboratories DRREDDY.NSIndia$12.5B+5%-4%9%32.0×30.7%+12.1%
Hansoh Pharma 3692.HKHong Kong$25.3B-3%+25%38%25.8×7.9%+10.8%

Questions

Who are Shionogi &'s main competitors?
Named competitors: Takeda (4502.T), Daiichi Sankyo (4568.T), Pfizer (PFE), GSK (GSK.L), Merck (MRK). The cockpit's measured peer set (industry) also includes Ascendis Pharma A/S (ASND), Exelixis (EXEL), Torrent Pharmaceuticals (TORNTPHARM.NS), Innovent Biologics (1801.HK), Swedish Orphan Biovitrum (SOBI.ST), Jazz Pharmaceuticals Public (JAZZ).
Is Shionogi & expensive compared with its peers?
On forward p/e it trades at 11.8× against a peer median of 25.8×, 4th cheapest of 20 in its peer set. For today's price to make sense, revenue must grow about 0% a year for seven years (Req g). Recent delivered growth is +11%, so the hurdle is -11 pp: the price already allows for a slowdown.
How has Shionogi & stock performed?
Over six months to 18 Nov 2026 the shares returned +3.1% against +5.4% for the median peer; over one year +24.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.